Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration
Phase of Trial: Phase IV
Latest Information Update: 26 Nov 2016
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.